4-1BB agonism: adding the accelerator to cancer immunotherapy (Q28079622)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Cariad Chester

series ordinal

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Holbrook E Kohrt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

1 reference

October 2016

1 reference

Cancer Immunology, Immunotherapy

1 October 2016

15 references

3 April 2019

19 June 2019

25 June 2019

31 July 2019

3 August 2019

9 August 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

15 December 2019

9 September 2020

23 September 2020

8 February 2021

17 references

3 April 2019

19 June 2019

25 June 2019

31 July 2019

3 August 2019

9 August 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

9 September 2020

23 September 2020

8 February 2021

65

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

10

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1243-1248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

2 June 2020

copyright license

15 references

3 April 2019

19 June 2019

25 June 2019

31 July 2019

3 August 2019

9 August 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

15 December 2019

9 September 2020

23 September 2020

on focus list of Wikimedia project

8 February 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

cDNA sequences of two inducible T-cell genes

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

TNF/TNFR family members in costimulation of T cell responses

20 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

20 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Targeting CD137 enhances the efficacy of cetuximab.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Effects of 4-1BB signaling on the biological function of murine dendritic cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

4-1BB signaling beyond T cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5035667

A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg.

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1829-2

Role of 4-1BB in immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1829-2

4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1829-2

Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1829-2

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1829-2

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

21 January 2018

1 reference

12 December 2020

Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework

1 reference

12 December 2020

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines

1 reference

12 December 2020

Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy

1 reference

12 December 2020

10.1007/S00262-016-1829-2

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

1019603888

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

PubMed publication ID

27034234

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27034234%20AND%20SRC:MED&resulttype=core&format=json